Related Experiment Video
Updated: Oct 12, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Identification of Pax protein inhibitors that suppress target gene expression and cancer cell proliferation
Shayna T J Bradford1, Edward Grimley1, Ann M Laszczyk2
1Department of Pathology, University of Michigan, BSRB 2049, 109 Zina Pitcher Drive, Ann Arbor, MI 48109, USA; Molecular and Cellular Pathology Graduate Program, University of Michigan, Ann Arbor, MI 48109, USA.
Abstract:
The Pax family of developmental control genes are frequently deregulated in human disease. In the kidney, Pax2 is expressed in developing nephrons but not in adult proximal and distal tubules, whereas polycystic kidney epithelia or renal cell carcinoma continues to express high levels. Pax2 reduction in mice or cell culture can slow proliferation of cystic epithelial cells or renal cancer cells. Thus, inhibition of Pax activity may be a viable, cell-type-specific therapy. We designed an unbiased, cell-based, high-throughput screen that identified triazolo pyrimidine derivatives that attenuate Pax transactivation ability. We show that BG-1 inhibits Pax2-positive cancer cell growth and target gene expression but has little effect on Pax2-negative cells. Chromatin immunoprecipitation suggests that these inhibitors prevent Pax protein interactions with the histone H3K4 methylation complex at Pax target genes in renal cells. Thus, these compounds may provide structural scaffolds for kidney-specific inhibitors with therapeutic potential.
Insights
Researchers identified novel compounds that inhibit Pax2, a gene linked to kidney diseases like polycystic kidney disease and renal cell carcinoma. These Pax2 inhibitors show potential for developing targeted kidney cancer therapies.
Area of Science:
- Developmental biology
- Molecular oncology
- Nephrology
Background:
- Pax genes, crucial for development, are often dysregulated in human diseases.
- Pax2 is normally absent in adult kidney tubules but overexpressed in polycystic kidney epithelia and renal cell carcinoma.
- Inhibiting Pax activity presents a potential cell-type-specific therapeutic strategy for kidney diseases.
Purpose of the Study:
- To identify novel inhibitors of Pax transactivation ability.
- To evaluate the therapeutic potential of these inhibitors in kidney cancer and polycystic kidney disease models.
Main Methods:
- An unbiased, cell-based, high-throughput screening approach was employed.
- Triazolo pyrimidine derivatives were identified as potential Pax transactivation inhibitors.
- In vitro assays were used to assess the effect of inhibitors on cell growth and gene expression.
Main Results:
- A novel compound, BG-1, was found to inhibit Pax2-positive cancer cell growth and target gene expression.
- BG-1 demonstrated minimal effects on Pax2-negative cells, indicating specificity.
- Chromatin immunoprecipitation revealed that inhibitors interfere with Pax protein interactions with the H3K4 methylation complex at target genes.
Conclusions:
- Triazolo pyrimidine derivatives are effective Pax transactivation inhibitors.
- These compounds show promise as scaffolds for developing kidney-specific therapies.
- Targeting Pax2 offers a potential therapeutic avenue for renal cell carcinoma and polycystic kidney disease.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
02:23Abnormal Proliferation
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:23Negative Regulator Molecules